Sumitomo Pharma Co (TSE:4506) PE Ratio without NRI: 5.33 (As of Jul. 09, 2026) — 64% Below Median


TSE:4506 Sumitomo Pharma Co Ltd TSE:4506
57 GF Score
Price 円1,432.50
GF Value 円833.08
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Sumitomo Pharma Co PE Ratio without NRI?

Sumitomo Pharma Co TSE:4506 -1.21% 57 PE Ratio without NRI is 5.33 as of Jul. 09, 2026, which is 64% below its 10-year median of 14.82. GuruFocus rates TSE:4506 with a GF Score™ of 57/100 and a GF Value™ of 円833.08 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 654 Drug Manufacturers companies, Sumitomo Pharma Co ranks better than 95.87% on this metric.

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-07-09), Sumitomo Pharma Co's share price is 円1432.50. Sumitomo Pharma Co's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was 円268.99. Therefore, Sumitomo Pharma Co's PE Ratio without NRI for today is 5.33.

During the past 13 years, Sumitomo Pharma Co's highest PE Ratio without NRI was 41.51. The lowest was 4.33. And the median was 14.82.

Sumitomo Pharma Co's EPS without NRI for the three months ended in Mar. 2026 was 円-2.04. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was 円268.99.

As of today (2026-07-09), Sumitomo Pharma Co's share price is 円1432.50. Sumitomo Pharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was 円268.99. Therefore, Sumitomo Pharma Co's PE Ratio (TTM) for today is 5.33.

During the past years, Sumitomo Pharma Co's highest PE Ratio (TTM) was 41.51. The lowest was 4.33. And the median was 14.82.

Sumitomo Pharma Co's EPS (Diluted) for the three months ended in Mar. 2026 was 円-2.04. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was 円268.99.

Sumitomo Pharma Co's EPS (Basic) for the three months ended in Mar. 2026 was 円-2.04. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was 円268.99.


Sumitomo Pharma Co  (TSE:4506) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


Sumitomo Pharma Co PE Ratio without NRI Related Terms


Sumitomo Pharma Co PE Ratio without NRI Historical Data

* Premium members only.

The historical data trend for Sumitomo Pharma Co's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sumitomo Pharma Co PE Ratio without NRI Chart

Sumitomo Pharma Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
PE Ratio without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.51 At Loss At Loss 12.25 7.72

Sumitomo Pharma Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.25 20.40 4.39 8.36 7.72

TSE:4506 vs ZTS, UTHR: PE Ratio without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sumitomo Pharma Co PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Sumitomo Pharma Co's PE Ratio without NRI falls into.


TSE:4506
57GF Score
Sumitomo Pharma Co Ltd TSE:4506
PE Ratio without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sumitomo Pharma Co PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

Sumitomo Pharma Co's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=1432.50/268.990
=5.33

Sumitomo Pharma Co's Share Price of today is 円1432.50.
Sumitomo Pharma Co's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円268.99.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio without NRI →
What does a PE Ratio without NRI of 5.33 mean?
Sumitomo Pharma Co (TSE:4506) has a PE Ratio without NRI of 5.33 as of Jul. 09, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Sumitomo Pharma Co and its competitors. This is 64% below median its historical median of 14.82. Over the past decade, Sumitomo Pharma Co's PE Ratio without NRI has ranged from 4.33 to 41.51. According to the industry distribution chart, Sumitomo Pharma Co ranks #27 out of 654 companies in the Drug Manufacturers industry, placing it in the top 4.1%.
Is Sumitomo Pharma Co's PE Ratio without NRI too high?
Sumitomo Pharma Co's current PE Ratio without NRI of 5.33 is 64% below median its 10-year median of 14.82. Over the past 10 years, this metric has ranged from a low of 4.33 to a high of 41.51. The Drug Manufacturers industry median PE Ratio without NRI is 20.65. Sumitomo Pharma Co's value of 5.33 is 74.2% below this industry median. Based on the distribution chart, Sumitomo Pharma Co ranks #27 out of 654 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sumitomo Pharma Co has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sumitomo Pharma Co's PE Ratio without NRI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sumitomo Pharma Co ranks #27 out of 654 companies for PE Ratio without NRI. This places Sumitomo Pharma Co in the top 4% of its industry — outperforming the majority of peers. The industry median PE Ratio without NRI is 20.65. Sumitomo Pharma Co's value of 5.33 is 74.2% below this benchmark. Historically, Sumitomo Pharma Co's own PE Ratio without NRI has ranged from 4.33 to 41.51 over the past decade. While the company's 10-year median is 14.82 vs. the industry median of 20.65, Sumitomo Pharma Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Drug Manufacturers company?
The median PE Ratio without NRI among Drug Manufacturers companies is 20.65, based on 654 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sumitomo Pharma Co's current PE Ratio without NRI of 5.33 is 74.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Sumitomo Pharma Co and its competitors. For the Drug Manufacturers industry, the median PE Ratio without NRI is 20.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sumitomo Pharma Co's current PE Ratio without NRI is 5.33, which is 64% below median its own 10-year median of 14.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sumitomo Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Sumitomo Pharma Co (TSE:4506) is currently considered Significantly Overvalued. The stock's GF Value™ is 円833.08, compared to a current price of 円1,432.50 — trading 72% above its estimated fair value. The current PE Ratio without NRI is 5.33, which is 64% below median its 10-year median of 14.82 and 74.2% below the Drug Manufacturers industry median of 20.65. Sumitomo Pharma Co's overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Sumitomo Pharma Co (TSE:4506), the current PE Ratio without NRI is 5.33 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sumitomo Pharma Co (TSE:4506) Overvalued in 2026?

Based on GuruFocus' analysis, Sumitomo Pharma Co stock appears to be overvalued. The current stock price of 円1,432.50 is trading 72% above its estimated GF Value™ of 円833.08. GuruFocus considers Sumitomo Pharma Co to be Significantly Overvalued.

Key valuation signals for TSE:4506:

  • PE Ratio without NRI: 5.33 (64% below median its 10-year median of 14.82)
  • GF Value™: 円833.08 vs. price of 円1,432.50 (72% above fair value)
  • GF Score™: 57/100 with 6 warning signs
  • Industry Position: 74.2% below the Drug Manufacturers median (#27 of 654)

No single metric tells the full story. See the TSE:4506 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sumitomo Pharma Co Business Description

Address 6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
57GF Score

Get the complete analysis for TSE:4506

PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,432.50
Price
円833.08
GF Value